Search results
Results from the WOW.Com Content Network
Common side effects include headache, trouble sleeping, sleepiness, and unsteadiness. [5] Serious side effects may include high blood lactate levels, psychiatric symptoms, and enlargement of the liver. [5] It should not be used in children. [7] If used during the first trimester of pregnancy harm to the baby may occur. [5]
Common side effects include headaches, fever, and nausea. [6] Serious side effects include liver problems, muscle damage, and high blood lactate levels. [6] It is commonly used in pregnancy and appears to be safe for the fetus. [6] ZDV is of the nucleoside analog reverse-transcriptase inhibitor (NRTI) class. [6]
If a pregnant woman presents in labor with an unknown HIV status and a positive rapid HIV test result or an infant has a high risk of HIV transmission in utero (for example, the mother was not taking antiretroviral drugs in the pre-pregnancy period or during pregnancy, the mother had not achieved viral suppression, or the mother experienced an ...
The combination is indicated for the treatment of human immunodeficiency virus 1 (HIV 1) infection in people weighing at least 14 kilograms (31 lb) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. [6] [7]
Common side effects include headache, tiredness, trouble sleeping, abdominal pain, weight loss, and rash. [5] Serious side effects may include high blood lactate levels and enlargement of the liver. [7] Use of this medication during pregnancy does not appear to harm the fetus, but this has not been well studied. [1]
Pregnancy category: ... is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. each ... The most common serious side effects are ...
The combination of Rekambys and Vocabria injection is intended for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/ml) with their current ARV treatment, and when the virus has not developed resistance to certain class of anti-HIV medicines called non-nucleoside reverse transcriptase ...
Didanosine became the second drug approved for the treatment of HIV infection in many other countries, including in the United States by the Food and Drug Administration (FDA) on 9 October 1991. Its FDA approval helped bring down the price of zidovudine (ZDV), the initial anti-HIV drug.